Home / Health / Ozempic, Wegovy May Ease Anxiety, Depression
Ozempic, Wegovy May Ease Anxiety, Depression
19 Mar
Summary
- Semaglutide linked to 44% reduced depression risk.
- Liraglutide also showed lower depression risk.
- Pregnancy risks differ based on diabetes or weight loss use.
Medications such as Ozempic and Wegovy, containing the active ingredient semaglutide, are showing potential benefits for mental health, according to new international research. These drugs, classified as GLP-1 receptor agonists, were analyzed for their impact on anxiety and depression.
A study drawing on Swedish health registries examined over 95,000 patients. It found that semaglutide was associated with a 44% reduced risk of worsening depression and a 38% reduced risk of anxiety. Liraglutide, another GLP-1 agonist, also showed a lower risk of worsening depression.
Researchers suggest semaglutide and liraglutide could be effective dual therapeutic options for conditions co-occurring with diabetes and obesity. Potential explanations for these effects range from weight loss and improved body image to direct neurobiological mechanisms.
In separate findings, Danish research investigated GLP-1 receptor agonists during early pregnancy. While exposure was linked to heightened pre-term birth risk when used for diabetes, this association was not observed among those using the medication for weight management. This suggests the underlying diabetes may be the causal factor.
